Prevalence and prognostic significance of adrenergic escape during chronic β-blocker therapy in chronic heart failure

European Journal of Heart Failure

Volumn 11, Issue 2, 2009, Pages 178-184

  Frankenstein, Lutz ^a   Zugck, Christian ^a   Schellberg, Dieter ^a   Nelles, Manfred ^a   Froehlich, Hanna ^a   Katus, Hugo ^a   Remppis, Andrew ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blocker; Adrenergic escape; Chronic heart failure; Prognosis

Indexed keywords

ADRENALIN; BISOPROLOL; CARVEDILOL; LOOP DIURETIC AGENT; METOPROLOL; NORADRENALIN; SPIRONOLACTONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEART RATE; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORADRENALIN BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; AGED; BLOOD; CHRONIC DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; EPINEPHRINE; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE;

EID: 64549136266     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn028     Document Type: Article

References (27)

1. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16(Suppl. N):103-106.
2. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-1057.
3. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, Caruso B, Zardini P. Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 89:403-407.
4. Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D, Moye LA, Pfeffer M. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur HeartJ 1998;19: 1552-1563.
5. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95:169-175.
6. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75:IV80-IV92.
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
8. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-442.
9. Krzeminski K, Nazar K, Cybulski G, Mikulski T. Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure. Clin Physiol Funct Imaging 2006;26:328-334.
10. Mattioli AV, Mattioli G. Neurohumoral changes in patients with heart failure treated chronically with beta-blockers. Cardiologia 1991;36:549-556.
11. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M, Francolini G, Diemberger I, Bacchi L, Rapezzi C, Ferrari R, Branzi A. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resyn-chronization therapy: time courses and prediction of response. Peptides 2006; 27:1776-1786.
12. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24: 1310-1320.
13. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadre-nergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825.
14. Frankenstein L, Nelles M, Slavutsky M, Schellberg D, Doesch A, Katus H, Remppis A, Zugck C. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 2007;26: 1033-1039.
15. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ, Task Force for the Diagnosis Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
16. Ratge D, Baumgardt G, Knoll E, Wisser H. Plasma free and conjugated catecholamines in diagnosis and localisation of pheochromocytoma. Clin Chim Acta 1983; 132:229-243.
17. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999;340:1872-1879.
18. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338: 107-115.
19. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100: 1056-1064.
20. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004;110:1437-1442.
21. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. EurJ Heart Fail 2004;6:539-545.
22. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angio-tensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
23. Newton GE, Parker JD. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996;94:353-358.
24. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E, BEST Investigators. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003;9:354-363.
25. Fowler MB, Lottes SR, Nelson JJ, Lukas MA, Gilbert EM, Greenberg B, Massie BM, Abraham WT, FranciosaJA, COHERE Participant Physicians. Beta-blocker dosing in community-based treatment of heart failure. Am Heart J 2007;153:1029-1036.
26. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H, MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/ XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-498.
27. Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U, Gottlieb S, Rashkow A, Wedel H, Bermann G, Kjekshus J, MERIT-HF Study Group. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005;45:252-259.